Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 3 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 221Carboplatin 214Cisplatin 202Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 113Cyclophosphamide 101Pemetrexed 100Dexamethasone 100Specimen Handling 98Oxaliplatin 96Magnetic Resonance Spectroscopy 96Radiotherapy 92Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 67durvalumab 65Lenalidomide 64atezolizumab 61Radiation 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × tisagenlecleucel × 1 year × Clear all
NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05888493 2026-04-17

LEDA

Novartis

Phase 3 Active not recruiting
109 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡